Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes.

Details

Serval ID
serval:BIB_030AF67BFB94
Type
Article: article from journal or magazin.
Collection
Publications
Title
Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes.
Journal
European Neurology
Author(s)
Rossetti A.O., Bromfield E.B.
ISSN
0014-3022
Publication state
Published
Issued date
2005
Peer-reviewed
Oui
Volume
54
Number
1
Pages
34-38
Language
english
Abstract
Treatment of status epilepticus (SE) has changed little over the last two decades, but the burden of this condition remains important. There is thus a need for alternative pharmacological therapies. Levetiracetam (LEV) has a wide spectrum of action and a favorable pharmacokinetic profile; however, little data exist regarding its use in SE. We identified patients with SE who received LEV, in a database comprising 127 SE episodes. Demographic, clinical and pharmacological data were analyzed, and compared to a control group consisting of 2 subjects from the database for each LEV patient, matched for age and sex. We identified 13 SE episodes occurring in 12 patients (10% of the database). Demographic, etiologic and clinical characteristics and outcome did not differ between the groups. Daily LEV dose ranged between 1,000-6,000 mg. Three patients were probable responders (23%), 1 responded to the treatment but subsequently died (8%), 4 were non-responders (31%, 1 died), and 5 had an undetermined response (38%). LEV may represent a useful alternative in the treatment of SE, particularly if a parenteral form of administration becomes available; to better define its role in this setting, prospective studies are needed.
Keywords
Adult, Aged, Aged, 80 and over, Anticonvulsants, Female, Humans, Male, Middle Aged, Piracetam, Status Epilepticus, Treatment Outcome
Pubmed
Web of science
Create date
14/05/2009 8:03
Last modification date
20/08/2019 13:25
Usage data